Abeona Therapeutics (ABEO) Net Income towards Common Stockholders (2011 - 2026)

Abeona Therapeutics' Net Income towards Common Stockholders history runs 16 years deep, the most recent figure standing at -$17.1 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 42.29% year-over-year to -$17.1 million; the TTM figure through Mar 2026 stood at $66.8 million (up 251.43% YoY), while the FY2025 annual figure was $76.6 million, up 220.25% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$17.1 million, up from -$35.3 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $124.3 million in Q2 2025, with the low at -$35.3 million in Q4 2025.
• The 5-year median for Net Income towards Common Stockholders is -$11.8 million (2023), against an average of -$6.9 million.
• Peak annual rise in Net Income towards Common Stockholders reached 1580.34% in 2025, while the deepest fall reached 279.89% in 2025.
• Abeona Therapeutics' Net Income towards Common Stockholders stood at -$7.1 million in 2022, then tumbled by 132.4% to -$16.6 million in 2023, then soared by 43.98% to -$9.3 million in 2024, then plunged by 279.89% to -$35.3 million in 2025, then jumped by 51.67% to -$17.1 million in 2026.
• Business Quant data shows ABEO's Net Income towards Common Stockholders at -$17.1 million in Q1 2026, -$35.3 million in Q4 2025, and -$5.2 million in Q3 2025.